NCT07578831 Comparative Effects of Kendall and Feldenkrais Exercise in Upper Crossed Syndrome
| NCT ID | NCT07578831 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Riphah International University |
| Condition | Upper Crossed Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 72 participants |
| Start Date | 2026-01-15 |
| Primary Completion | 2026-05-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 72 participants in total. It began in 2026-01-15 with a primary completion date of 2026-05-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Upper Cross Syndrome (UCS) is a prevalent musculoskeletal disorder characterized by muscular imbalances and postural dysfunction. Kendall Method and Feldenkrais Method are physiotherapy exercise programs aimed at reducing pain and improving cervical position sense, CV angle and function. This study compares their effects on pain, CV angle, cervical position sense, and disability in individuals with upper cross syndrome. This will be a randomized Controlled trial conducted on 72 participants. Data will be collected from Sikander Medical Complex, Gujranwala by using non-probability convenience sampling technique. Adults aged 20 to 50 years with upper cross syndrome, confirmed by Craniovertebral Angle less than 50 degrees and experiencing symptoms for more than four weeks, will be included in this study. Individuals with cervical spondylosis, spondylolisthesis, disc prolapse, trauma-related cervical injuries, or a history of shoulder surgery will be excluded. Group A will receive Kendall Method along with conservative physiotherapy, while Group B will receive Feldenkrais Method combined with conservative physiotherapy. Each session will last 30 minutes-40 minutes for the primary intervention and 15-20 minutes for conventional therapy-administered three times per week for five weeks. Pre- and post-treatment evaluations will include the Numeric Pain Rating Scale (NPRS), CV angle (measured via Image J), Cervical position Sense (assessed via HRE) and functional disability (measured via NDI). Data will be analyzed using SPSS version 27.0.
Eligibility Criteria
Inclusion Criteria: * Male subjects between 20-50 years * Female subjects between 20-50 years * Cranio-vertebral angle less than 50 degrees * Subjects who had been experiencing neck pain for more than 3 months * Slouched sitting for more than four hours per day * Usage of handheld devices while reading, working, and travelling * Pain intensity score between 4 to 10 on NPRS * NDI\>10 scores between 10 and 34 * Tight pectoralis major muscle Exclusion Criteria: * Surgeries of the cervical spine within past 1 year * Surgeries or fracture to the shoulder joint * Cervical instability * Cervical Radiculopathy * Neurological disorders such as cervical spondylosis, spondylolisthesis, disc prolapse and rheumatic disease
Contact & Investigator
Aiman Hameed, MSPT(CP)
PRINCIPAL INVESTIGATOR
Riphah International University
Frequently Asked Questions
Who can join the NCT07578831 clinical trial?
This trial is open to participants of all sexes, aged 20 Years or older, up to 50 Years, studying Upper Crossed Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07578831 currently recruiting?
Yes, NCT07578831 is actively recruiting participants. Contact the research team at Rabiya.Noor@riphah.edu.pk for enrollment information.
Where is the NCT07578831 trial being conducted?
This trial is being conducted at Lahore, Pakistan.
Who is sponsoring the NCT07578831 clinical trial?
NCT07578831 is sponsored by Riphah International University. The principal investigator is Aiman Hameed, MSPT(CP) at Riphah International University. The trial plans to enroll 72 participants.